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ABSTRACT
This was a quality improvement project that will allow improvements to be made in
healthcare services offered and the overall health status of Stage IV metastatic lung cancer
patients receiving palliative care referrals. Data was collected retrospectively from
electronic medical records of Stage IV metastatic lung cancer patients with palliative care
referrals between January 2019 and March 2020. The palliative care referrals between
January 2019 and August 2019 were given per oncologist discretion in timing compared to
August 2019-March 2020 when new patients received nurse navigator driven palliative
care referrals immediately upon diagnosis. Data analysis looked at correlations for each
group as presented regarding treatment dates, ethnicity, and gender. An attempt to
determine quality of life measures through the PROMs survey was made; however, there
was not enough data to make a determination due to the limited number of completed
surveys.
The study found that nurse navigator driven palliative care referrals did not increase
palliative care received by patients diagnosed with Stage IV metastatic lung cancer. There
was no significant difference between palliative care patients receiving a referral based on
oncologist discretion versus receiving immediate referrals through a nurse navigator;
therefore, the effect of palliative care referrals upon initial diagnosis on the severity of
anxiety, sadness, and pain in patients with Stage IV metastatic lung cancer, as well as
narcotic need, and treatments received is indeterminate.
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Chapter 1: Introduction
Introduction
Metastatic non-small cell lung cancer is a devastating disease that causes multiple
symptoms resulting in poor quality of life (Temel et al., 2010, p.733). It is the most
common cancer-related cause of death throughout the world and has a prognosis of less
than one year upon diagnosis. (Temel et al., 2010, p.733). Metastatic stage IV lung cancer
is a type of cancer that has spread from the lungs throughout the body, which can be
difficult to treat. People with metastatic lung cancer have a poor prognosis and need
palliative care involvement (Leonard, 2019, para. 2; Rowland, 2010).
However, involvement of palliative care should occur at the time of diagnosis to
improve patient symptoms and quality of life, as well as extend the patients’ life
expectancy (Rowland, 2010). This chapter will cover information about the importance of
palliative care in metastatic lung cancer, as well as the purpose and questions of the study.
This study will identify what effect, if any, does immediate, nurse navigator driven
palliative care referrals at time of diagnosis have on patients with metastatic non-small cell
lung cancer.
Background to Problem
Palliative care is defined as an interdisciplinary medical specialty that aims to
optimize quality of life for patients with serious, life-limiting illnesses and their families
(Rhee, Mchugh, Tun, Gerhart, & O’Mahony, 2014; Kelley & Morrison, 2015; Kelley &
Meier, 2010). Palliative care is provided in conjunction with curative therapies and lifeprolonging medical treatments (Kelley & Meier, 2010). Improving the quality of life for
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patients with Stage IV metastatic lung cancer is a significant challenge due to the
progressive nature of the disease (Temel et al., 2010).
The study conducted by Temel et al. (2010) showed statistically significant
improvements in early implementation of palliative care combined with traditional
oncologic treatment in patients with metastatic non-small cell lung cancer. The patients in
the study were evaluated and a prolonged survival rate of approximately 2 months and
improved quality of life with the early palliative care implementation was noted (Temel et
al., 2010). “Physicians tend to perceive palliative care as the alternative to life-prolonging
or curative care rather than as a simultaneously delivered adjunct to disease-focused
treatment” (Kelley & Meier, 2010, p.781).
The study by Temel et al. confirms the beneficial outcomes of a simultaneous care
plan in patients who receive palliative care and disease-specific treatments at the initial
time of diagnosis (Kelley & Meier, 2010). By identifying a link between early palliative
care referral and patient outcomes, healthcare providers will be able to implement early
palliative care into their routine practice in order to improve outcomes in patients with
metastatic lung cancer.
Little research has been performed on specific elements of palliative care that are
provided and received by patients (Kelley & Meier, 2010). By studying the actual
components of palliative care that are deemed beneficial, evidence will be established for
best medical practice. Palliative care is indicated in various patient populations and should
be evaluated in other disease populations and medical facilities in order to assess the
benefit of new approaches (Kelley & Meier, 2010).
Problem Statement
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Studies have shown that immediate palliative care involvement upon the initial
diagnosis of Stage IV metastatic lung cancer patients led to healthcare improvements.
Improving quality of life for patients with Stage IV metastatic lung cancer is a significant
challenge due to the progressive nature of the disease (Temel et al., 2019). Patients who
received early palliative care implementation had improved quality of life, longer life
expectancy, and the quality of care in comparison to patients who received later
standardized palliative care consults (Temel et al., 2010; Ma et al., 2019).
Purpose
The purpose of the study is to assess the impact and implications of early initiated
palliative care consultation on the outcomes of metastatic lung cancer patients at Regions
Hospital. The study will determine what effect, if any, does immediate palliative care
consults issued by nurse navigators upon the initial diagnosis of Stage IV metastatic lung
cancer have on patients. Additional factors among patients in the study will be analyzed
statistically to further look at other variables conducive to improved patient outcomes.
Significance of Problem
The study has significance for both current healthcare providers and patients
diagnosed with Stage IV metastatic lung cancer. The quality improvement design of the
study will allow improvements to be made in healthcare services offered and the overall
health status of patients in the studied groups (U.S. Department of Health and Human
Resources and Services Administration Editorial Team, 2011). “Physicians tend to
perceive palliative care as the alternative to life-prolonging or curative care rather than as a
simultaneously delivered adjunct to disease-focused treatment” (Kelley & Meier, 2010, p.
781). The study may encourage Stage IV metastatic lung cancer patients to discuss the
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benefits of early palliative care consults with their oncologists. The findings from the study
may prompt further research into expanded implementation of immediate palliative care
consults in patients with other forms of cancer and chronic terminal illnesses.
Research Question
The following research question will be explored in this study: does an immediate
palliative care referral increase palliative care?
Limitations of Study
Delimitations to the study include studying patients with Stage IV metastatic lung
cancer at Regions Hospital in St Paul, Minnesota. The study will include patients who
received immediate nurse navigator driven palliative care consults upon initial diagnosis
and patients who received palliative care consults later in the disease progression under
physician discretion in the years 2018 to 2019. These delimitations were set to adequately
assess the implications of the new palliative care guidelines set at Regions Hospital in this
patient population.
Limitations to the study include the limited time period in which research is
obtained, the patient population studied in a very specific location versus a nationwide
study including other healthcare facilities implementing the new palliative care guidelines.
Researcher bias limitation needs to be evaluated due to the promising literature indicating
improved quality of life for patients who do receive the immediate palliative care consults
upon initial diagnosis.
Definition of Terms
The following definitions will be used frequently throughout the research paper.
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Cancer: “cells growing out of control in the body” (“The American Cancer Society
Medical and Editorial Team,” 2019).
Epidemiology: “the branch of medicine dealing with the incidence and prevalence of
disease in large populations and with detection of the source and cause in epidemics of
infectious disease” (“Epidemiology,” 2019).
Hospice: “A) a health-care facility for the terminally ill that emphasizes pain control and
emotional support for the patient and family, typically refraining from taking extraordinary
measures to prolong life. B) Similar program of care and support for the terminally ill at
home” (“Hospice,” 2019).
Lung cancer: “a type of cancer that originates in the lungs” (“The American Cancer
Society Medical and Editorial Team,” 2019).
Metastasis: “the transference of disease-producing organisms or of malignant cancerous
cells to other parts of the body by way of the blood or lymphatic vessels or membranous
surfaces” (“Metastasis,” 2019).
Non-Small Cell Lung Cancer: “a type of lung cancer that includes adenocarcinoma and
squamous cell carcinoma” (“The American Cancer Society Medical and Editorial Team,”
2019).
Palliative Care: “medical care focused on improving the quality of life of patients with
serious illness, as by treating symptoms and providing emotional support” (“Palliative
care,” 2019).
Conclusion
This chapter covered information about the importance of palliative care in
metastatic lung cancer, as well as the purpose and questions of the study. This study will
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identify what effect, if any, immediate nurse navigator driven palliative care referrals at the
time of diagnosis has on patient outcomes in metastatic lung cancer. The next chapter will
review lung cancer sites of metastases, treatment options, palliative care approaches, and
research studies correlating with improved patient outcomes.
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Chapter 2: Literature Review
Introduction
The following literature review will discuss the impact and implications of early
initiated palliative care consultations on the outcomes of metastatic lung cancer patients.
The literature review will provide a background into lung cancer itself, discussing the
epidemiology, various types, lung cancer metastasis sites, and survival rates of patients. It
will also provide a background into what palliative care is, and how immediate palliative
care referrals have impacted the healthcare system today.
Lung Cancer
Epidemiology. According to the American Cancer Society (2019a), “lung cancer
(both small cell and non-small cell) is the second most common cancer in both men and
women” (para. 2). “Lung cancer accounts for about 13% of new cancer cases,” and there is
estimated to be “228,150 new cases of lung cancer (116,440 in men and 111,710 in
women),” as well as “142,670 deaths from lung cancer (76,650 in men and 66,020 in
women)” in 2019 (“The American Cancer Society Medical and Editorial Content Team,”
2019a, para. 3).
The largest cause of cancer related death is lung cancer, which is associated with
more deaths than cancers from etiologies of breast, colon, and prostate combined (“The
American Cancer Society Medical and Editorial Content Team,” 2019a, para. 4).
Generally, lung cancer occurs in people ages 45 to 70 years old with the vast majority of
people being diagnosed ages 65 or greater. Patients diagnosed with lung cancer are, on
average, 70 years old (“The American Cancer Society Medical and Editorial Content
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Team,” 2019a, para. 5). According to the American Cancer Society (2019a), 1 out of 15
men and 1 out of 17 women will develop lung cancer during their lives (para. 6).
Main Types.
Non-small cell lung cancer. The most common type of lung cancer is non-small
cell lung cancer (NSCLC), which presents as 80 to 85% of lung cancer cases (“The
American Cancer Society Medical and Editorial Content Team,” 2019d, para. 9). The three
primary subtypes of NSCLC include adenocarcinoma, squamous cell carcinoma, and large
cell carcinoma, which have comparable treatment strategies and prognoses (“The
American Cancer Society Medical and Editorial Content Team,” 2019d, para. 9).
Adenocarcinoma. Adenocarcinoma affects lung cells that produce and secrete
mucus within the lungs, and it is generally located in the outer lungs (“The American
Cancer Society Medical and Editorial Content Team,” 2019d, para. 10 & 12). This is the
most common lung cancer in non-smokers, but it is predominantly found in previous and
present smokers (“The American Cancer Society Medical and Editorial Content Team,”
2019d, para. 11).
Adenocarcinoma “is more common in women than in men, and it is more likely to
occur in younger people than other types of lung cancer.… and is more likely to be found
before it as spread” according to the American Cancer Society (2019d, para. 11 & 12).
Patients diagnosed with adenocarcinoma usually have a better prognosis than patients with
other lung cancers (“The American Cancer Society Medical and Editorial Content Team,”
2019d, para. 13).
Squamous cell carcinoma. Squamous cell carcinoma (SCC) affects the central,
inner lining of squamous cells within the airway of the lungs (“The American Cancer
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Society Medical and Editorial Content Team,” 2019d, para. 14). In most scenarios, SCC
occurs from toxins acquired through smoking (“The American Cancer Society Medical and
Editorial Content Team,” 2019d, para. 14).
Large cell carcinoma. Large cell carcinoma (LCC) is a very fast-growing,
undifferentiated cancer that may present anywhere within the lungs (“The American
Cancer Society Medical and Editorial Content Team,” 2019d, para. 15). LCC has the
capability to spread rapidly making treatment difficult. For this reason, LCC – although a
NSCLC – is comparable to small cell lung cancer (“The American Cancer Society Medical
and Editorial Content Team,” 2019d, para. 15).
Small cell lung cancer. Small cell lung cancer (SCLC) occurs in 10 to 15% of lung
cancer cases (“The American Cancer Society Medical and Editorial Content Team,”
2019d, para. 17). With quick growth and spread – being much faster than NSCLC – SCLC
has already spread upon diagnosis in 70% of patients (“The American Cancer Society
Medical and Editorial Content Team,” 2019d, para. 17). Treatment of SCLC through
chemotherapy and radiation is generally successful; however, most patients with successful
initial treatment of SCLC will recur (“The American Cancer Society Medical and Editorial
Content Team,” 2019d, para. 17).
Risk Factors. The most common risk factor for lung cancer resulting in
approximately 90% of lung cancer cases and 80% of lung cancer related deaths is tobacco
smoking (“The American Cancer Society Medical and Editorial Content Team,” 2019b,
para. 4; de Groot, Wu, Carter, & Munden, 2018). People that smoke have a much greater
chance of developing lung cancer than non-smokers, and the risk increases to a greater
extent the longer and more packs that are smoked. Additionally, cigar and pipe smokers
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have a similar likelihood of developing lung cancer compared to cigarette smokers (“The
American Cancer Society Medical and Editorial Content Team,” 2019b, para. 5&6).
Secondhand smoke or environmental smoke is another risk factor that increases
chances of lung cancer development and causes 7,000+ deaths from lung cancer annually
(“The American Cancer Society Medical and Editorial Content Team,” 2019b, para. 7).
Secondhand smoke (SHS) is defined by the involuntary exposure of nonsmokers to
tobacco smoke from other individuals smoking (Samet & Sockrider, 2018). SHS contains
over 7,000 chemical compounds, 70 of which are known carcinogens. Due to the link of
secondhand smoke to lung cancer in nonsmokers, it has been classified as a group A
carcinogen (Samet & Sockrider, 2018). Cotinine is the product formed after the chemical
nicotine enters the body (Hukkanen, Jacob, & Benowitz, 2005).
Thirdhand smoke (THS) is defined as residual particles of tobacco smoke that settle
on surfaces indoors (Jacob et al., 2017). THS clings to clothes, furniture, curtains, walls,
bedding, carpet, and vehicles long after the smoking has ceased. THS bound to an object’s
surface can persistently affect indoor air quality for days, weeks, and/or months, and
provides adequate time for chemical reactions to occur between the THS and normal
pollutants in indoor air (Jacob et al., 2017). Thirdhand smoke has become a recent interest
in research due to some tobacco specific nitrosamines (TSNAs) with high carcinogenic
potential (Jacob et al., 2017).
Other risk factors that may lead to lung cancers include exposures to radon,
asbestos, radioactive materials, radiation therapy, arsenic, and air pollution (“The
American Cancer Society Medical and Editorial Content Team,” 2019b). Additionally,
patients with family histories of lung cancer or with personal previous history of lung
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cancer are at a greater risk (“The American Cancer Society Medical and Editorial Content
Team,” 2019b, para. 22&23).
Metastases. Metastatic lung cancer is a condition that occurs when cancer cells
from an original tumor within the lung spread to other locations in the body. Lung cancer
is transmitted throughout the body by vascular and/or lymphatic systems, and generally
spreads to the adrenal glands, brain, bones, liver, or contralateral lung. It is possible for
other organs to become involved in later disease stages (Popper, 2016).
Due to the asymptomatic and aggressive nature of lung cancer, many of these
cancers do not present until metastasizing to stage IV. This makes lung cancer the leading
cause of cancer mortality worldwide (Poleri, 2003). In 2019, it is projected that nearly
142,670 deaths will occur from lung cancer according to physician researchers Kathryn
Arbour and Gregory Riely (2019). Of the presenting lung cancer cases, approximately 85%
will be non-small cell lung cancers (NSCLC) (Govindan et al., 2006).
The most recent staging system for lung cancer seen in Table 1 is the eighth edition
TNM staging system. The TNM staging system utilizes three descriptive categories which
includes tumor characteristics, local lymph node involvement, and distant metastases
(Thomas & Gould, 2019). The eighth edition has three further subcategories for those with
distant metastases: M1a, M1b and M1c. M1a is assigned to those with metastases confined
solely to the thoracic region (Thomas & Gould, 2019). M1b is assigned to those with a
single metastasis outside of the thoracic region (Thomas & Gould, 2019). M1c comprises
those with multiple extra-thoracic metastases (Thomas & Gould, 2019).
The TNM with M1a, M1b, and M1c criteria are utilized to stage both small cell
lung cancer (SCLC) and NSCLC diagnoses (Thomas & Gould, 2019). Metastatic lung
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cancer is now classified as either IVA, in which no or a single extra-thoracic metastasis
exists, or IVB which involves multiple extra-thoracic metastases (Thomas & Gould, 2019).
The IVA/IVB staging system is intended to better reflect disease prognosis and to further
guide treatment planning (Thomas & Gould, 2019). Based on eighth edition staging, IVA
two-year prognosis is 23% and five-year prognosis is 10% while IVB two-year prognosis
is 10% and five-year prognosis is 0% (Thomas & Gould, 2019). The TNM staging system
can be found in Appendix A.
Survival Rates. According to the American Lung Association (2019), “the fiveyear survival rate (18.6 percent) is lower than many other leading cancer sites, such as
colorectal (64.5 percent), breast (89.6 percent) and prostate (98.2 percent)” (“American
Lung Association Scientific and Medical Editorial Review Panel,” 2019, para. 6). Lung
cancer patients with localized disease have a 56% five-year survival rate, but very few
cases are diagnosed while the disease is still localized (“American Lung Association
Scientific and Medical Editorial Review Panel,” 2019, para. 6). In contrast, patients with
metastatic cancer spreading systemically have a 5% five-year survival rate (“American
Lung Association Scientific and Medical Editorial Review Panel,” 2019, para. 6). Of the
people diagnosed with lung cancer, greater than 50% die within 12 months (“American
Lung Association Scientific and Medical Editorial Review Panel,” 2019, para. 6).
Non-Small Cell Lung Cancer Metastases
At the time of diagnosis, “40% of new NSCLC cases have distant metastases”
(Yang et al., 2019). In a retrospective study of 1,542 NSCLC patients, distant metastasis
was present in 729 patients (Tamura et al., 2015). The most commonly affected sites of
metastases in order of prevalence include “bone, lung, brain, adrenal gland, liver and extra-
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thoracic lymph node” (Tamura et al., 2015). Metastatic spread in NSCLC often first
involves the lymph nodes and in TNM staging is "a powerful prognostic predictor” (Yang
et al., 2019).
Nodal involvement is highly associated with multi-organ metastases. NSCLC
patients with low nodal involvement (low N scores in the TNM staging system), typically
have metastases confined to the thorax (associated with M1a classification) (Yang et al.,
2019). With multiple nodes involved, as in N3 classification, patients often have spread of
metastases outside of the thoracic region (associated with M1b classification) (Yang et al.,
2019).
“Bone metastasis is the most common in patients with lung adenocarcinoma”
(Liao, Fan, & Wang, 2019). Bone involvement is believed to adversely affect survival due
to the weakening of the skeletal system and associated pathologies including “pathological
fractures, spinal cord compression and hypercalcemia of malignancy” (Tamura et al.,
2015). Treatment for bone metastases includes systemic chemotherapy, radiation therapy
for localized bone lesions, or surgery to prevent and treat pathological fractures
(Lilenbaum, 2019). Average overall survival of those with bone metastases was five
months (Liao et al., 2019).
Over the course of the disease, “brain metastases will develop in approximately
25% to 50% of patients with NSCLC with 10% to 20% of them having [brain metastases]
when the disease is first diagnosed” (Khalifa, Amini, Popat, Gaspar, & Faivre-Finn, 2016).
Patients who develop brain metastases after diagnosis will do so within two years of
diagnosis (Dempke et al., 2015). Traditional treatment options for brain metastases
include surgery, whole-brain radiation therapy in combination with steroid therapy, and
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systemic chemotherapy (Dempke et al., 2015). However, many of these options are
limited due to the nature of brain involvement (Dempke et al., 2015).
Brain metastases have been correlated with poor performance status, which
disqualifies many individuals from surgical treatment (Dempke et al., 2015). Whole brain
radiotherapy when added to surgical treatment exhibits effective local control, however no
improvements were noted in overall survival for NSCLC (Khalifa et al., 2016). Systemic
chemotherapy also has limitations in efficacy for brain metastases (Dempke et al., 2015).
Systemic chemotherapy agents have general poor blood brain barrier penetration, with only
a 15% to 30% brain metastasis response rate depending on agent used (Dempke et al.,
2015).
Newer targeted therapies are promising with higher intracranial activity, but further
study is necessary to determine improved outcomes in overall survival (Dempke et al.,
2015). Brain metastases resulting from NSCLC overall adversely affect quality of life and
survival, with the median overall survival being three to 15 months (Khalifa et al., 2016).
Metastases to the liver are an unfavorable factor in NSCLC prognosis (Tamura et al.,
2015). Chemotherapy agents used in the treatment of NSCLC are not properly metabolized
or activated by a liver containing cancerous metastases (Tamura et al., 2015).
Therefore, liver metastases typically do not respond well to systemic chemotherapy
(Tamura et al., 2015). Liver dysfunction resulting from metastases may disqualify NSCLC
from continued chemotherapy use (Tamura et al., 2015). When comparing isolated organ
metastasis for most commonly afflicted metastatic sites, stage IV NSCLC patients with
“liver metastasis alone had the worst prognosis, with a median overall survival of four
months” (Liao et al., 2019).
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Small Cell Lung Cancer Metastases
Most patients with SCLC have extensive-stage disease at the time of presentation,
characterized by distant metastasis with possible pleural effusions or lymph node
involvement on the contralateral side (Kelly, 2018). The most common sites for metastasis
in SCLC include the liver, adrenal glands, bone and bone marrow, and brain (Glisson &
Byers, 2019). Metastatic involvement of the bone marrow can be detected in up to 30% of
asymptomatic patients (Glisson & Byers, 2019). Bone marrow involvement is also present
in 15% to 30% of patients at presentation (Glisson & Byers, 2019); however, only 2% to
6% of patients have bone marrow as a solitary site of metastasis (Glisson & Byers, 2019).
Brain metastases are found in 15% of patients at diagnosis, including those without
symptoms (Glisson & Byers, 2019). Brain involvement in SCLC is often associated with a
poorer prognosis; metastases to the brain tend to be numerous and distributed throughout
all areas of the brain (Loeffler, 2018). Prognosis for specific metastatic sites is challenging
to determine due to confounding variables of multiple metastatic sites (Glisson & Byers,
2019). However, increasing number of organs involved is correlated with worse prognosis
and involvement of brain, bone marrow and the liver are considered unfavorable
prognostic factors (Glisson & Byers, 2019).
The main therapy for all patients with extensive-stage SCLC is systemic
chemotherapy with or without added radiation therapy (Kelly, 2018), regardless of
metastatic sites. The clinical decision to add radiation therapy is for palliative rather than
curative therapy (Glisson & Byers, 2019). Despite a high response to both therapy options,
SCLC relapse is common within months (Kelly, 2018). The average survival for extensive-
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stage SCLC is eight to 13 months from time of diagnosis, with less than 5% of patients
surviving past two years (Kelly, 2018).
Background of Palliative Care
Approaches. When caring for chronically ill patients and discussing end of life
care, it is imperative to understand the difference between palliative care and hospice.
Palliative care is defined as an interdisciplinary medical specialty that aims to optimize
quality of life for patients with serious, life-limiting illnesses and their families (Rhee,
Mchugh, Tun, Gerhart, & O’Mahony, 2014; Kelley & Morrison, 2015; Kelley & Meier,
2010). Palliative care is provided as an adjunct with curative therapies and life-prolonging
medical treatments (Kelley & Meier, 2010). In order to meet the needs of seriously ill
patients, the palliative care team includes medical professionals from physicians, nursing,
social work, nutrition, rehabilitation, pharmacy, and chaplains (Kelley & Morrison, 2015).
“Hospice care becomes appropriate when curative treatments are no longer
beneficial, when burdens of treatments exceed the benefits, or when patients are entering
the last weeks to months of life” (Kelley & Meier, 2010, p.781). In 1967, Dame Cicely
Saunders developed hospice in hopes of creating a care plan for patients dying from
advanced cancer (Kelley & Morrison, 2015). Patients qualify for hospice when they have
been given a diagnosis of six months or less to live and elect to discontinue restorative
treatments (Kelley & Morrison, 2015). Table 2, from “Palliative Care for the Seriously Ill,”
compares palliative care and hospice by looking at the model of care, patients who are
eligible for each program, the location in which each program is implemented, and
reimbursement factors (Kelley & Morrison, 2015).
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Table 2
Palliative care versus hospice (Kelley & Morrison, 2015, p. 748)

Components. Several core components that all palliative care plans encompass,
include treatment of physical and psychological symptoms, spiritual support, and
communication skills to provide goals of healthcare (Kelley & Morrison, 2015). Primary
care physicians are trained to address all of the core components, allowing for the
complicated cases to be addressed by palliative care specialists (Kelley & Morrison, 2015).
Most primary clinicians, however, have not had formal training in palliative care topics.
Physical symptoms commonly associated with palliative care patients include pain,
dyspnea, cough, anorexia, and fatigue (Chandrasekar, Tribett, & Ramchandran, 2016).
Routine clinical histories, review of systems, and primary assessment used to identify such
symptoms lead to enhanced patient comfort (Blinderman & Billings, 2015). Figure 1
shows the wide variety of symptoms present in chronic illnesses and the prevalence of
each symptom based on the diagnosis of the patient (Kelley & Morrison, 2015).
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Figure 1
Symptoms comparison in advanced illnesses (Kelley & Morrison, 2015, p. 749)

Evidence suggests that most patients suffering from chronic illnesses wish to
express their spirituality concerns with their physicians (Kelley & Morrison, 2015).
Several studies have shown a correlation between improved quality of life in cancer
patients whose spiritual needs were recognized (Kelley & Morrison, 2015; Nawawi et al.,
2012). A study based on survey results asked advanced lung cancer patients to classify the
importance of seven factors that contributed to their decisions regarding medical treatment
(Nawawi, Balboni, & Balboni, 2012). “Patients’ faith in God was considered by patients
and their caregivers to be a key factor in medical decision-making- ranked only second
behind the ability of the treatment to cure disease” (Nawawi et al., 2012, p. 270). When
asked about roles in addressing spiritual concerns of patients, less than 50% of physicians
considered it an important part of healthcare (Kelley & Morrison, 2015).
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Communication among providers and patients has been studied extensively in the
past decade. Palliative care requires communication of serious news, prognosis
uncertainty, discussing treatment options, and establishing overall goals of care. “Clinical
studies have shown the use of NURSE (naming, understanding, respecting, supporting, and
exploring) have improved effective communication regarding empathy of care” (Kelley &
Morrison, 2015, p. 750). Prospective cohort studies assessing patients with stage IV cancer
who actively discussed car plan goals with their physician show evidence of a decreased
incidence of mortality in an ICU (Kelley & Morrison, 2015).
Delivery Modes. Palliative care in the United States is traditionally utilized in
acute care hospitals (Kelley & Morrison, 2015). Within a decade, palliative care programs
have amplified by approximately 150% (Kelley & Morrison, 2015). Ninety percent of
larger hospitals containing 300+ beds, in addition to 67% of hospitals with 50 beds
currently have palliative care programs (Kelley & Morrison, 2015). In acute care hospitals,
interdisciplinary teams address palliative care needs. Current changes in delivery models
include automatic palliative care referrals for patients requiring both a palliative care team
and another specialty team, such as oncology (Kelley & Morrison, 2015). Community
based palliative care is traditionally thought of as hospice programs. Hospice programs are
available to patients choosing to discontinue therapeutic treatment after prognosis of six
months or less to live (Kelley & Morrison, 2015).
Community based palliative care programs are now being utilized to benefit
chronically ill patients who do not qualify for hospice (Kelley & Morrison, 2015). After
the Affordable Care Act (ACA) was passed, many private payers and Medicare patients
have taken advantage of community-based palliative care programs to help reduce
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healthcare costs and improve quality of life (Kelley & Morrison, 2015). The community
palliative care team continue to use an interdisciplinary team and focus on symptom
management and caregiver support at home (Kelley & Morrison, 2015). Even though the
community-based palliative care idea is fairly new, randomized clinical trials have shown
patients with chronic illnesses gain increased symptom management, greater satisfaction
scores, and reduced hospitalization rates (Kelley & Morrison, 2015).
Lastly, long-term care encompasses a vast need for palliative care teams. Nearly
1.8 million United States citizens reside in nursing homes (Kelley & Morrison, 2015).
“More than 25% of elderly persons die in nursing homes, 67% of persons with advanced
dementia live their finals days in this setting” (Kelley & Morrison, 2015, p.751). Three
models of palliative care utilized in nursing home settings, including hospice care,
palliative care consultation from an external source, and internal palliative care teams that
work specifically in the nursing home (Kelley & Morrison, 2015).
Nursing homes and hospice agencies can form agreements to provide services to
residents when appropriate (Kelley & Morrison, 2015). “Hospice utilization in nursing
homes is associated with higher family satisfaction, decreased rates of invasive therapies,
and better symptom management” (Kelley & Morrison, 2015, p. 752). The palliative care
consultation model is one which a palliative care physician consults nursing home
physicians; which is billed under Medicare Part B (Kelley & Morrison, 2015). Internal
palliative care teams in nursing homes are specifically utilized with residents diagnosed
with advanced stage dementia (Kelley & Morrison, 2015).
Challenges. “Physicians tend to perceive palliative care as the alternative to lifeprolonging or curative care rather than as a simultaneously delivered adjunct to disease-
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focused treatment” (Kelley & Meier, 2010, p.781). The scope of palliative care teams
ranges from institution to institution and some lack integral elements, like social work and
chaplains (Rhee et al., 2014). This challenge is further exaggerated by the specific
palliative care team and practice approach, that can be drastically different depending on
the healthcare facility (Ma et al., 2019; Rhee et al., 2014). Furthermore, palliative care
teams are often nonexistent in rural community hospitals (Rhee et al., 2014). Currently, it
is estimated that for every 1,300 patients diagnosed with a chronic illness, there is one
palliative care physician available (Rhee et al., 2010).
Each year, nearly 300 hospital and palliative care fellows graduate; yet the number
of palliative care physicians is not enough to meet the demands necessary within the
healthcare system (Rhee et al., 2014). Medical programs are actively trying to address this
shortage by integrating primary palliative care into curriculums. The curriculum would
include pain management, care goal discussions, the delivery of unfortunate news to
patients and families, which would allow primary physicians to address basic palliative
care needs (Rhee et al., 2010).
Early Palliative Care Implementation
Metastatic Non-Small Cell Lung Cancer. Former research has indicated the
benefit of early palliative care. In one such study, the effect of early palliative care on
quality of life and end of life care was examined in patients newly diagnosed with
metastatic, non-small cell lung cancer (Temel et al., 2010). A group of 151 participants
diagnosed within the past eight weeks with metastatic NSLC were selected from
Massachusetts General Hospital in Boston and randomly placed into two different groups
(Temel et al., 2010).
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The control group received only standard oncologic care, while the intervention
group received early palliative care in addition to standard oncologic care (Temel et al.,
2010). Standard oncologic care was not determined by the study. The intervention group
received at least one palliative care visit per month with additional visits scheduled if
requested by the patient, oncologist or palliative care team (Temel et al., 2010). Palliative
care guidelines were adapted from the National Consensus Project for Quality Palliative
Care and the specific care provided was documented in electronic medical records (Temel
et al., 2010). Of the care provided, physical and psychosocial symptom assessments,
assistance with treatment decisions, determining care goals, and coordinating care based on
the needs of each patient were evaluated (Temel et al., 2010).
To determine the effect of early palliative care on quality of life, researchers
utilized the Functional Assessment of Cancer Therapy-Lung (FACT-L) scale to assess
physical, emotional, social and functional wellness (Temel et al., 2010). The Hospital
Anxiety and Depression scale was used to assess for changes in mood (Temel et al., 2010).
Both the control and intervention group completed the FACT-L and Hospital Anxiety and
Depression assessments at the start of the study and again at 12 weeks into the study
(Temel et al., 2010). To analyze end of life care, researchers obtained data from medical
records (Temel et al., 2010).
The results of the study at the 12-week assessment showed when patients received
additional early palliative care versus standard oncologic care alone, depression scores
were lower (16% versus 38%) and quality of life was improved (FACT-L score of 98
versus 91.5) (Temel et al., 2010). Higher median survival rates were also seen in the
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intervention group with median survival being 11.6 months as compared to 8.9 months for
the control group (Temel et al., 2010).
Medical Intensive Care Unit. The study conducted by Ma et al. (2019) in two
medical intensive care units (ICUs) at Barnes Jewish Hospital in St. Louis, Missouri was
groundbreaking in evaluating early palliative care consultations in high-risk ICU patients.
The purpose of this study was to determine the impact of early triggered palliative care
consultation on the outcomes of high-risk ICU patients (Ma et al., 2019). “Patients 18 years
and older consecutively admitted on weekdays to the MICUs were screened for study
enrollment using a tool comprised of nine predetermined palliative care criteria to identify
patients at high risk for morbidity and mortality based on severe or chronic organ
dysfunction” (Ma et al., 2019, p. 2).
There were 242 patients that met the study’s baseline criteria, including 117
patients in the intervention group and 116 patients in the control group (Ma et al., 2019).
The control group consisted of patients receiving palliative care consultations at the
discretion of the MICU physicians (Ma et al., 2019). The intervention group consisted of
patients that received palliative care consults within 48 hours of admission to the ICU (Ma
et al., 2019). The interprofessional palliative care team at Barnes Jewish Hospital was
made up of a palliative care physician, nurse practitioners, a fellow specializing in
palliative care, social workers, and a chaplain (Ma et al., 2019).
The patients in the intervention group were followed by this palliative care team
until they were discharged (Ma et al., 2019). The consultations provided by the palliative
care team addressed various issues regarding the patients’ care. This included a “chart
review of the patient’s hospitalization, meeting with the patient and available healthcare
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proxies, identification of physical and emotional needs of the patient and family,
discussion with the primary team on how best to meet those needs, and communication
between all parties with respect to goals, values, and treatment decisions” (Ma et al., 2019,
p. 3).
The primary outcome evaluated from the Ma et al. (2019) study was the number of
patients in the ICU who changed their code status to do not resuscitate (DNR)/ do not
intubate (DNI). The patients in the intervention group (50.5%) that changed code statuses
to DNR/DNI was significantly higher than that of the control group (23.4%) (Ma et al.,
2019). Secondary outcomes were also evaluated among the patients, assessing “ICU
length of stay, discharge to hospice care, days on the ventilator, tracheostomy placement,
CPR, mortality, post discharge ER visits, and hospital readmission rates” (Ma et al., 2019,
p. 4-6).
There was no significant difference between the intervention and control group in
hospital mortality, ICU length of stay, or 30-day mortality (Ma et al., 2019). Statistically
significant variations between the intervention and control group included transfer to
hospice care (18.6%-intervention vs 4.9%-control), tracheostomy placement (1.0%intervention vs 7.8%- control), and overall MICU operating costs ($9,860-intervention vs
$15,660- control) (Ma et al., 2019). While this study was conducted in a single healthcare
facility, it serves as an integral approach with early palliative care intervention in ICU
high-risk patient populations (Ma et al., 2019).
Conclusion
The current literature reveals that early implementation of palliative care consults
in Stage IV metastatic lung cancer patients can improve quality of life, overall life
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expectancy, and the quality of care in comparison to patients who received later
standardized palliative care consults (Temel et al., 2010; Ma et al., 2019). While the
studies conducted by Temel et al. (2010) and Ma et al. (2019) show statistically significant
variables in the intervention groups who received early palliative care consults, there is
little research done on specific elements of palliative care that are provided and received by
patients.
By studying the actual components of palliative care that are deemed beneficial,
evidence will be established for best medical practice. With modification of the study
design, additional factors among patients will be analyzed statistically to further look at
other variables conducive to improved patient outcomes. This study may encourage Stage
IV metastatic lung cancer patients to discuss the benefits of early palliative care consults
with their oncologists. The findings from the study may prompt further research into
expanded implementation of immediate palliative care consults in patients with other
forms of cancer and chronic terminal illnesses.
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Chapter 3: Methods
Introduction
The purpose of the study is to assess the impact and implications of early initiated
palliative care consultation on the outcomes of metastatic lung cancer patients at Regions
Hospital. Additional factors among patients in the study will be analyzed statistically to
further look at other variables conducive to improved patient outcomes. The research
question that will be addressed in this study include the following: to what effect, if any,
does immediate palliative care consults issued upon the initial diagnosis of Stage IV
metastatic lung cancer have on patient anxiety, sadness, pain, narcotic need, and cancer
treatments at one and six months?
Study Design
The study design is a quality improvement project that will allow improvements to
be made in healthcare services offered and the overall health status of patients in the
studied groups. A group of participants will be identified based on pre-existing criteria, in
this case, patients diagnosed with Stage IV metastatic lung cancer. Data will be collected
retrospectively from electronic medical records regarding Regions Hospital Stage IV
metastatic lung cancer patients with palliative care referrals in the past two years.
The population will be studied retrospectively from January 2019-August 2019
when patients were referred to palliative care per oncologist preference in timing compared
to August 2019-March 2020 when new patients received nurse navigator driven palliative
care referrals immediately upon diagnosis. Approval to access deidentified data from
Regions Hospital was obtained and can be found in Appendix B.
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Data analysis will include sorting data into an Excel spreadsheet based on patients’
age, ethnicity, interpreter need, claim of a religion, type of lung cancer (small cell or nonsmall cell), brain metastasis, number of comorbidities (chronic obstructive pulmonary
disease, congestive heart failure, dialysis, depression, anxiety, vascular disease,
cardiovascular disease), baseline ECOG performance status, baseline pain severity, and
baseline narcotic need, as well as baseline and six month patient reported outcome
measures (PROMs) (Appendix C) responses regarding the severity of anxiety, sadness,
pain, narcotic need and dyspnea. The researchers will be looking for correlations in
patterns within both groups of patients and their outcomes based on the palliative care
referral. The Excel spreadsheet with outcomes analyzed can be found in Appendix D.
Study Site
The participants were selected from Regions Hospital oncology clinic in St. Paul,
Minnesota. This location was chosen as they had recently implemented a program of nurse
navigator driven immediate palliative care referrals for patients with Stage IV metastatic
lung cancer. Participants were selected based on their diagnosis of Stage IV metastatic lung
cancer. A letter of intent for research affiliation with Regions Hospital and Dr. Peter
Hurley can be found in Appendix E.
Population
Participants were required to be age eighteen or greater and could be any gender
and any ethnicity. Inclusion criteria includes patients who were diagnosed with Stage IV
metastatic lung cancer prior to the early palliative care initiation period, and patients who
were diagnosed with Stage IV metastatic lung cancer after the early palliative care
initiation was implemented at Regions Hospital. The appropriate Internal Review Board
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(IRB) measures were taken to gain permission from Region’s and Bethel to perform the
quality improvement project. The Region’s IRB approval is in Appendix F and Bethel IRB
approval in Appendix G.
Criteria for exclusion were those patients who did not receive a diagnosis of Stage
IV metastatic lung cancer, patients not treated at Regions Hospital after diagnosis of Stage
IV metastatic lung cancer, and those with other forms of Stage IV cancer, not including
specifically lung cancer. In order to detect a significant difference with a standard
deviation of two, at least 50 subjects are needed for each group analyzed. The subjects will
be studied retrospectively from January 2019-August 2019 when patients were referred to
palliative care per oncologist preference in timing compared to August 2019-March 2020
when new patients received palliative care referrals placed by nurse navigators
immediately upon diagnosis. The total study subject goal is 100 chart reviews consisting of
50 from each group in which data was analyzed using the excel spreadsheet tool.
Instrument and Procedure
The study’s researchers developed the Excel spreadsheet used to collect
experimental data. The spreadsheet tool will be reviewed to determine whether it is all
encompassing to complete the goals of evaluating the target population. The panel of
reviewers will include one physician who works regularly with the target population, and
one quality improvement physician. After review, the spreadsheet will be edited to meet all
suggestions to achieve appropriate readability.
Data Analysis
The data collected from Regions Hospital will be analyzed using either MANOVA,
individualized t tests, or a MANCOVA test. Analysis will include correlational studies
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and trend analysis comparing the time of palliative care referral with patient outcomes
measured through the severity of patient anxiety, sadness, and pain, as well as narcotic
need and treatment received at one, three, and six months. The quantitative data will be
organized into tables and charts to determine other significant trends in patient
demographics within each group.
Reliability and Validity
Since all subject charts will be analyzed using the same spreadsheet, every
measurement will be consistent and could be reproduced; it will therefore be reliable. A
panel of reviewers will evaluate the spreadsheet for validity, further enhancing the
reliability of the research instrument. Demographic data about the patients will be
collected, allowing for population-related external validity.
Dispensation of Data
The collected data will be transferred to a hard drive and placed in the possession
of the Bethel University Physician Assistant Program research coordinator. The data will
be stored in a secure, locked space. Data will be destroyed in accordance with the policies
of the Physician Assistant Program.
Limitations and Delimitations
Delimitations to the study include studying patients with Stage IV metastatic lung
cancer at Regions Hospital in St. Paul, Minnesota. The study will include patients who
received nurse navigator driven immediate palliative care consults upon initial diagnosis in
August 2019 through March 2020 and patients who received palliative care consults later
in the disease progression under physician discretion between January 2019 and August
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2019. These delimitations were set to adequately assess the implications of the new
palliative care guidelines set at Regions Hospital in this patient population.
Limitations to the study include the limited time period in which research is
obtained, the patient population studied in a very specific location versus a nationwide
study including other healthcare facilities implementing the new palliative care guidelines.
Researcher bias limitation needs to be evaluated due to the promising literature indicating
improved quality of life for patients who do receive the immediate palliative care consults
upon initial diagnosis.
Conclusion
In conclusion, this study was performed to examine the effects of immediate
palliative care referrals upon diagnosis on the severity of anxiety, sadness, and pain in
patients with Stage IV metastatic lung cancer, as well as narcotic need and treatments
received. This was done by comparing measured outcomes in patients referred to palliative
care by oncologist preference with those referred immediately by nurse navigators upon
diagnosis. The intent of the study was to collect, analyze, and compare measured outcomes
between the two groups. The collected data and analysis will be reviewed in the following
chapters.
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Chapter 4: Results
Introduction
Chapter four contains the results of data analysis. Data is organized according to
two main participant groups: Group 1 (patient population studied retrospectively from
January 2019-August 2019 with palliative care referrals per oncologist discretion of
timing) compared to group 2 (patient population studied retrospectively from September
2019-March 2020 with palliative care referrals driven by a nurse navigator immediately
upon diagnosis). Correlations for each group are presented regarding treatment dates,
ethnicity, and gender.
Statistical Analysis
Statistical analyses were performed using JASP, a statistical software to determine
correlations between the groups and variables collected. The quantitative data was
organized into tables and charts to determine other significant trends in patient
demographics – which included treatment dates, ethnicity, and gender – within each group.
Each statistical analysis performed revealed high p-values when comparing variables
which is shown in the tables below.
As seen in Table 3, there was no significant difference between treatment dates and
palliative care referrals. This indicates that palliative care referrals placed under physician
discretion versus driven by a nurse navigator did not improve the number of immediate
palliative care referrals for patients with Stage IV metastatic lung cancer. The correlation
between palliative care referrals placed for patients of white and non-white ethnicities was
statistically analyzed in Table 4, which reveals that there is no significant difference in
palliative care referrals placed for patients with different ethnicities.
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Legend:
- 1: patient population studied January 2019-August 2019 (palliative care referrals
per oncologist discretion)
- 2: patient population studied September 2019-March 2020 (palliative care referrals
per nurse navigator immediately upon diagnosis)
- 3: male gender
- 4: female gender
Table 3
Comparison between treatment dates and palliative care referral
Contingency Tables
Palliative Care Referral (Y=1, N=2)
Treatment Dates
No
Yes
Total
Count
28.000
31.000
59.000
1
Expected count
28.320
30.680
59.000
% within row
47.458 %
52.542 % 100.000 %
Count
20.000
21.000
41.000
2
Expected count
19.680
21.320
41.000
% within row
48.780 %
51.220 % 100.000 %
Count
48.000
52.000 100.000
Total
Expected count
48.000
52.000 100.000
% within row
48.000 %
52.000 % 100.000 %
Chi-Squared Tests
Value df
p
Χ²
0.017 1
0.896
N
100
There is no significant difference between treatment dates and palliative care referral, χ2
(df =1, N = 100) = 0.017, p = 0.896. 1 correlates with patients from January 2019 through
August 2019. 2 correlates with September 2019 to March 2020.
Table 4
Comparison between ethnicity and palliative care referral
Contingency Tables
Palliative Care Referral (Y=1, N=2)
Ethnicity
No
Yes
Total
Count
10.000
13.000
23.000
Non-White Expected count
11.152
11.848
23.000
% within row
43.478 %
56.522 % 100.000 %
Count
38.000
38.000
76.000
White
Expected count
36.848
39.152
76.000
% within row
50.000 %
50.000 % 100.000 %
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Contingency Tables

Palliative Care Referral (Y=1, N=2)
Ethnicity
No
Yes
Total
Count
48.000
51.000
99.000
Total
Expected count
48.000
51.000
99.000
% within row
48.485 %
51.515 % 100.000 %
Chi-Squared Tests
Value df
p
Χ² 0.301 1
0.583
N
99
There is no significant difference between ethnicity and palliative care referral, χ2 (df =1, N
= 99) = 0.301, p = 0.583.
Table 5 and Table 6 demonstrate that there was no significant difference between
treatment date and length of palliative care referral from diagnosis. Early palliative care
referral within 30 days of diagnosis occurred in 35.593 percent of patients in group 1 under
physician discretion compared to 39.024 percent of patients in group 2 under nurse
navigator driven referral. Data analysis for this study determined that palliative care
referrals did not significantly occur more immediately through a nurse navigator in group 2
versus by physician discretion in group 1. However, as seen in Table 6 the length of
palliative care referral trended toward a shorter mean through a nurse navigator compared
to by physician discretion, 49.810 days compared to 81.000 days, respectively.
Table 5
Comparison between treatment dates and length of palliative care referral from
diagnosis
Contingency Tables
Length of Palliative Care Referral from
Diagnosis (Categories)
Treatment
Early (<30
None
Late (>30 days) Total
Date
days)
Count
28.000
21.000
10.000
59.000
1
Expected
28.320
21.830
8.850
59.000
count
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Contingency Tables
Treatment
Date

% within
row
Count
Expected
2
count
% within
row
Count
Expected
Total
count
% within
row
Chi-Squared Tests
Value df
p
Χ²
0.450 2
0.798
N
100

Length of Palliative Care Referral from
Diagnosis (Categories)
Early (<30
None
Late (>30 days)
days)

Total

47.458 %

35.593 %

16.949 % 100.000 %

20.000

16.000

5.000

41.000

19.680

15.170

6.150

41.000

48.780 %

39.024 %

48.000

37.000

15.000

100.000

48.000

37.000

15.000

100.000

48.000 %

37.000 %

12.195 % 100.000 %

15.000 % 100.000 %

There is no significant difference between treatment date and length of palliative care
referral from diagnosis, χ2 (df =1, N = 100) = 0.450, p = 0.798.
Table 6
Independent samples t-test, test of equality variances, and group descriptives for length
of palliative care referral from diagnosis between groups 1 and 2
Independent Samples T-Test

t
df
p Cohen's d
Length of Palliative Care Referral from Diagnosis (Days) 1.024 50.000 0.311
0.289
Assumption Checks
Test of Equality of Variances (Levene's)

F df p
Length of Palliative Care Referral from Diagnosis (Days) 2.877 1 0.096
Group Descriptives
Length of Palliative Care Referral from Diagnosis
(Days)

Group N Mean
1

SD

SE

31 81.000 128.665 23.109
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Group Descriptives

Group N Mean SD
SE
2
21 49.810 65.027 14.190

There was no significant difference between the length of palliative care referral from
diagnosis for group 1 (M = 81.0) and group 2 (M = 49.81), t(50) = 1.024, p = 0.311, d =
0.289.
Table 7 includes data analyzing gender and palliative care referral. This data was
collected to determine if either male or female gender impacted patient likelihood of
palliative care referral independent from treatment date group. Of the 54 males and 46
females included in this study, 51.852 percent of males and 52.174 percent of females
received palliative care referrals. Statistical analysis demonstrates that there was no
significant difference between gender and palliative care referrals, indicating gender did
not impact receival of palliative care referral.
Table 7
Comparison between gender and palliative care referral
Contingency Tables
Gender (F=4, M=3)
3

4

Total
Chi-Squared Tests

Count
Expected
count
% within row
Count
Expected
count
% within row
Count
Expected
count
% within row

Palliative Care Referral (Y=1,
N=2)
No
Yes
26.000
28.000
25.920
48.148 %
22.000
22.080
47.826 %
48.000
48.000
48.000 %

28.080

Total
54.000
54.000

51.852 % 100.000 %
24.000
46.000
23.920

46.000

52.174 % 100.000 %
52.000 100.000
52.000

100.000

52.000 % 100.000 %
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Contingency Tables
Gender (F=4, M=3)
Value df p
Χ²
0.001 1 0.974
N
100

Palliative Care Referral (Y=1,
N=2)
No
Yes

Total

There is no significant difference between gender and palliative care referral, χ2 (df =1, N
= 100) = 0.001, p = 0.974.
Additional data was collected and analyzed to determine if there was a significant
difference in length of palliative care referral from diagnosis between male and female
gender. This data is summarized in Table 8 and Table 9. Of the 100 patients included in
this study, 33.333 percent of males and 41.304 percent of females received early palliative
care referrals within 30 days of diagnosis. Statistical analysis demonstrates that there was
no significant difference between male or female gender and length of palliative care
referral from diagnosis. This indicates that gender did not impact likelihood of receiving
early palliative care referral within 30 days of diagnosis.

Table 8
Comparison between gender and length of palliative care referral from diagnosis
Contingency Tables

Gender (F=4, M=3)

3
4

Count
Expected
count
% within
row
Count

Length of Palliative Care Referral from
Diagnosis (Categories)
Early (<30
Late (>30
None
days)
days)
26.000
18.000
10.000
25.920

19.980

48.148 %

33.333 %

22.000

19.000

8.100

Total
54.000
54.000

18.519 % 100.000 %
5.000

46.000
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Contingency Tables

Gender (F=4, M=3)

Total

Expected
count
% within
row
Count
Expected
count
% within
row

Length of Palliative Care Referral from
Diagnosis (Categories)
Early (<30
Late (>30
None
days)
days)
6.900

Total

22.080

17.020

46.000

47.826 %

41.304 %

48.000

37.000

15.000

100.000

48.000

37.000

15.000

100.000

48.000 %

37.000 %

10.870 % 100.000 %

15.000 % 100.000 %

Chi-Squared Tests
Value df p
Χ² 1.396 2 0.498
N
100
There is no significant difference between gender and length of palliative care referral
from diagnosis, χ2 (df = 2, N = 100) = 1.396, p = 0.498.
Table 9
Independent samples t-test, test of equality variances, and group descriptives for length
of palliative care referral from diagnosis between groups 3 and 4
Independent Samples T-Test

t
df
p Cohen's d
Length of Palliative Care Referral from Diagnosis (Days) 0.514 50.000 0.610
0.143
Assumption Checks
Test of Equality of Variances (Levene's)

F df p
Length of Palliative Care Referral from Diagnosis (Days) 0.121 1 0.729
Group Descriptives
Length of Palliative Care Referral from Diagnosis
(Days)

Group N Mean

SD

SE

3

28 75.571 118.390 22.374

4

24 60.042 95.970 19.590
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There was no significant difference between the length of palliative care referral from
diagnosis for group 3 (M = 75.571) and group 4 (M = 60.042), t(50) = 0.514, p = 0.610, d =
0.143.
Conclusion
Statistical results from the data analysis were included in this chapter. The small
sample size of our groups, in addition to limited patient reported outcome responses, made
analysis of the variables difficult for the demographics of treatment dates, ethnicity, and
gender between palliative care referrals and length of palliative care referrals. Chapter 5
will include an interpretation and conclusion of the study results from Chapter 4.
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Chapter 5: Conclusion
Introduction
With the growing amount of evidence indicating the promise in early palliative care
implementation, not only in metastatic lung cancer patients, but in all patients with chronic
disease states, this research project served to analyze what effect, if any, does immediate
palliative care consults issued by nurse navigators upon the initial diagnosis of Stage IV
metastatic lung cancer have on patients? Based on studies that linked early palliative care
implementation to improved outcomes regarding survival rate, quality of life, and code
status transition (Temel et al., 2010; Ma et al., 2019), this study anticipated that the
PROMs surveys completed by patients would reveal a significant difference between the
two groups in regard to patient reported outcomes of pain, anxiety, and narcotic need.
Additional factors among patients in the study, including gender and ethnicity, were
analyzed statistically to further look at other variables conducive to improved patient
outcomes. The following research question is addressed in this section; does a nurse
navigator driven palliative care referral increase palliative care?
Summary of Results
Based on the collected data, it was found that nurse navigator driven palliative care
referral did not increase palliative care received by patients diagnosed with Stage IV
metastatic lung cancer. There was no statistically significant difference in the number of
patients who received palliative care between those who received referral based on
oncologist discretion and those who received a nurse navigator driven referral at the time
of diagnosis. Additionally, there was no statistically significant difference found between
the two groups for the length of time it took to receive palliative care referral from the time
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of diagnosis. Demographic variables were analyzed to determine if any differences in
palliative care referral existed among patients of different gender or ethnicity. For each of
these variables, no significant difference was found for receiving palliative care referral.
The results demonstrating no difference in the number of patients who received
palliative care between the two groups receiving palliative care referrals immediately from
nurse navigators versus physician timed referrals were not as expected, which was
disappointing due to promising literature that was previously reviewed. The Temel et al
study assessed the quality of life and mood of patients diagnosed with metastatic non-small
cell lung cancer at baseline and again at 12 weeks. They utilized the Functional
Assessment of Cancer Therapy-Lung (FACT-L) scale and the Hospital Anxiety and
Depression Scale to evaluate these factors. Participants assigned to the early initiated
palliative care group had higher FACT-L scores, indicating higher quality of life (P=0.03)
and fewer depressive symptoms (P=0.01) than those receiving standardized palliative care
at the discretion of physicians (Temel et al., 2010). Overall, early initiation of palliative
care in metastatic non-small cell lung cancer patients resulted in prolongation of life by
about 2 months, improved quality of life, and less depressive mood symptoms (Temel et
al., 2010).
Interpretation of our study findings suggest oncologist determined palliative care
referral was optimized prior to the implementation of nurse navigator driven referral.
Additional interpretation of results indicates the nurse navigator driven referral system was
not a truly automatic referral system as there was no statistically significant difference
found between the two groups for the length of time it took to receive palliative care
referral from the time of diagnosis. Furthermore, the results indicated that delivery of
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palliative care for each group was independent of demographic variables. However, it is
important to note that this study involved both a limited sample size and limited time frame
of study in addition to a limited number of PROMs surveys to evaluate and statistically
analyze the data. Further research involving a larger sample size is therefore necessary to
determine the validity of these results, as well as implementing a more automatic system
for both palliative care referrals and PROMs survey completion.
Due to the limited number of PROMs surveys completed by patients diagnosed
with Stage IV metastatic lung cancer, there is not a correlation with the literature review
regarding patient outcomes as it remains unclear what effect nurse navigator driven
palliative care referrals had on patient outcomes measured through anxiety, pain, narcotic
need, and treatment. An attempt to determine quality of life measures through the PROMs
survey was made; however, there was not enough data to make a determination due to the
limited number of completed surveys. Further research requiring completion of the
PROMs surveys is needed to determine any significant differences that may exist between
the two groups for these outcome measures.
Literature review did reveal previous studies that have shown that immediate
palliative care involvement upon the initial diagnosis of Stage IV metastatic lung cancer
patients led to healthcare improvements. Patients who received early palliative care
implementation had improved quality of life, longer life expectancy, and the quality of care
in comparison to patients who received later standardized palliative care consults (Temel et
al., 2010; Ma et al., 2019). Little research has been performed on specific elements of
palliative care that are provided and received by patients (Kelley & Meier, 2010). By
studying the actual components of palliative care that are deemed beneficial, evidence will
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be established for best medical practice. Palliative care is indicated in various patient
populations and should be evaluated in other disease populations and medical facilities in
order to assess the benefit of new approaches (Kelley & Meier, 2010).
Limitations
Limitations to the study include utilizing a nurse navigator driven palliative care
referral instead of a completely automatic palliative care referral. Despite efforts by nurse
navigators, palliative care referrals were not 100% automatic for patients diagnosed with
Stage IV metastatic lung cancer. Furthermore, a limited number of patient reported
outcome measures (PROMs) surveys were completed by patients diagnosed with and being
treated for Stage IV metastatic lung cancer requiring palliative care referrals. The
unavailability of all the patients’ PROMs surveys from lack of completion by patients
resulted in an incomplete study with little data for statistical analysis.
Other limitations to note include the limited time period in which research was
obtained, the patient population studied in a very specific location versus a nationwide
study including other healthcare facilities implementing the new palliative care guidelines.
The study was performed in a single hospital with a specific group of oncologists and
palliative care providers, which limits comparison to other locations and different types of
chronic illnesses that would benefit from palliative care. Additionally, researcher bias
needs to be evaluated due to the promising literature indicating improved quality of life for
patients who do receive the immediate palliative care consults upon initial diagnosis.
Recommendations for Further Research
If this study were repeated, the researchers recommend a larger sample size
consisting of more varied demographic groups. Ideally, each demographic group would
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have approximately the same number of participants to avoid results that are weighted
toward one specific chronic illness. This may prompt further research into expanded
implementation of immediate palliative care consults in patients with other forms of cancer
and chronic terminal illnesses.
Additionally, results could be improved if patients were required to fill out the
PROMs surveys at monthly appointments to indicate if nurse navigator driven palliative
care referrals increase palliative care at Region’s Hospital. This could be improved if
PROMs surveys were administered for patients to fill out during their initial intake with
nursing staff at appointments similar to administering a Patient Health Questionnaire-9
(PHQ-9) survey prior to an annual physical appointment. The PROMs surveys could be
uploaded immediately into the electronic medical record (EMR) by nursing staff allowing
for greater patient completion of the survey. This would allow for baseline outcomes to be
compared with outcomes once initiating the automatic palliative care referral system.
Another consideration for future research includes the implementation of automatic
palliative care referrals through EMR systems at the time of diagnosis rather than utilizing
nurse navigator driven referrals. Automatic palliative care referrals would allow a truly
immediate palliative care referral that could only be missed with malfunctioning of the
EMR software system utilized by the hospital. If working properly through the EMR,
automatic palliative care referrals would ensure consistency in referral placement for all
patients at the time of diagnosis.
Conclusions
This was a quality improvement project that will allow improvements to be made in
healthcare services offered and the overall health status of Stage IV metastatic lung cancer
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patients receiving palliative care referrals. Data was collected retrospectively from
electronic medical records of Stage IV metastatic lung cancer patients with palliative care
referrals between January 2019 and March 2020. The palliative care referrals between
January 2019 and August 2019 were given per oncologist discretion in timing compared to
August 2019-March 2020 when new patients received nurse navigator driven palliative
care referrals immediately upon diagnosis. Data analysis looked at correlations for each
group as presented regarding treatment dates, ethnicity, and gender. An attempt to
determine quality of life measures through the PROMs survey was made; however, there
was not enough data to make a determination due to the limited number of completed
surveys.
This study found that nurse navigator driven palliative care referrals did not
increase palliative care received by patients diagnosed with Stage IV metastatic lung
cancer. There was no significant difference between palliative care patients receiving a
referral based on oncologist discretion versus receiving referrals through a nurse navigator;
therefore, the effect of immediate palliative care referrals upon initial diagnosis on the
severity of anxiety, sadness, and pain in patients with Stage IV metastatic lung cancer, as
well as narcotic need, and treatments received is indeterminate.
Literature review did reveal previous studies that have shown that immediate
palliative care involvement upon the initial diagnosis of Stage IV metastatic lung cancer
patients led to healthcare improvements. Patients who received early palliative care
implementation had improved quality of life, longer life expectancy, and the quality of care
in comparison to patients who received later standardized palliative care consults (Temel et
al., 2010; Ma et al., 2019). Little research has been performed on specific elements of
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palliative care that are provided and received by patients (Kelley & Meier, 2010). By
studying the actual components of palliative care that are deemed beneficial, evidence will
be established for best medical practice. Palliative care is indicated in various patient
populations and should be evaluated in other disease populations and medical facilities in
order to assess the benefit of new approaches (Kelley & Meier, 2010).
In conclusion, there was no difference in palliative care referrals placed by
physician discretion versus those driven by nurse navigators. In order to improve this
process, we would suggest a new system that would require patients willing to complete
PROMs surveys to fill out the survey at monthly appointments to indicate if nurse
navigator driven palliative care referrals increase palliative care. This could be improved if
PROMs surveys were administered to patients during their initial intake with nursing staff
at appointments. The PROMs surveys could be completed in the electronic medical record
(EMR) directly or uploaded immediately by the nurses, allowing for greater completion of
the survey. This would allow for baseline outcomes to be compared with outcomes once
initiating the automatic palliative care referral system. Additionally, implementation of
automatic palliative care referrals through EMR at the time of diagnosis could be utilized
instead of nurse navigator driven referrals. Once these suggestions have been made, an
additional quality improvement project could be initiated to analyze Stage IV metastatic
lung cancer patients’ quality of life with early implemented palliative care.
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Appendix A – Table 1: TNM staging (8th edition)
Table 1
TNM staging system (“The American Cancer Society Medical and Editorial Content
Team,” 2019c)
AJCC

Stage

Stage

grouping

Stage description*
The main tumor can’t be assessed for some reason, or cancer

Occult

TX

cells are seen in a sample of sputum or other lung fluids, but the

(hidden)

N0

cancer isn’t found with other tests, so its location can’t be

cancer

M0

determined (TX). The cancer is not thought to have spread to
nearby lymph nodes (N0) or to distant parts of the body (M0).

Tis
0

N0
M0

The tumor is found only in the top layers of cells lining the air
passages, but it has not invaded deeper into other lung tissues
(Tis). The cancer has not spread to nearby lymph nodes (N0) or
to distant parts of the body (M0).
The cancer is a minimally invasive adenocarcinoma. The

IA1

T1mi

tumor is no larger than 3 centimeters (cm) across, and the part

N0

that has invaded into deeper lung tissues is no more than ½ cm

M0

across. The cancer has not spread to nearby lymph nodes (N0)
or to distant parts of the body (M0).
OR

T1a

The tumor is no larger than 1 cm across, it has not reached the

N0

membranes that surround the lungs, and it does not affect the
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M0

main branches of the bronchi (T1a). The cancer has not spread
to nearby lymph nodes (N0) or to distant parts of the body
(M0).
The tumor is larger than 1 cm but no larger than 2 cm across. It

IA2

T1b

has not reached the membranes that surround the lungs, and it

N0

does not affect the main branches of the bronchi (T1b). The

M0

cancer has not spread to nearby lymph nodes (N0) or to distant
parts of the body (M0).
The tumor is larger than 2 cm but no larger than 3 cm across. It

IA3

T1c

has not reached the membranes that surround the lungs, and it

N0

does not affect the main branches of the bronchi (T1c). The

M0

cancer has not spread to nearby lymph nodes (N0) or to distant
parts of the body (M0).
The tumor has one or more of the following features (T2a):
•

It is larger than 3 cm but not larger than 4 cm across.

•

It has grown into a main bronchus but is not within 2 cm

T2a
IB

of the carina (the point where the windpipe splits into

N0

the left and right main bronchi) and it is not larger than 4

M0

cm across.
•

It has grown into the visceral pleura (the membranes
surrounding the lungs) and is not larger than 4 cm
across.
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•

It is partially clogging the airways (and is not larger than
4 cm across).

The cancer has not spread to nearby lymph nodes (N0) or to
distant parts of the body (M0).
The tumor has one or more of the following features (T2b):
•

It is larger than 4 cm but not larger than 5 cm across.

•

It has grown into a main bronchus but is not within 2 cm
of the carina (the point where the windpipe splits into
the left and right main bronchi) and it is larger than 4 cm

T2b
IIA

N0

but not larger than 5 cm across.
•

M0

The tumor has grown into the visceral pleura (the
membranes surrounding the lungs) and is larger than 4
cm but not larger than 5 cm across.

•

The tumor is partially clogging the airways (and is larger
than 4 cm but not larger than 5 cm across).

The cancer has not spread to nearby lymph nodes (N0) or to
distant parts of the body (M0).
The tumor is no larger than 3 cm across, has not grown into the
T1a/T1b/T1c membranes that surround the lungs, and does not affect the
N1

main branches of the bronchi (T1). It has spread to lymph nodes

M0

within the lung and/or around the area where the bronchus
enters the lung (hilar lymph nodes). These lymph nodes are on
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the same side as the cancer (N1). The cancer has not spread to
distant parts of the body (M0).

OR
The tumor has one or more of the following features (T2):

IIB

•

It is larger than 3 cm but not larger than 5 cm across.

•

It has grown into a main bronchus, but is not within 2
cm of the carina (the point where the windpipe splits
into the left and right main bronchi) and it is not larger
than 5 cm across.

T2a/T2b

•

N1
M0

It has grown into the visceral pleura (the membranes
surrounding the lungs) and is not larger than 5 cm.

•

It is partially clogging the airways (and is not larger than
5 cm).

The cancer has also spread to lymph nodes within the lung
and/or around the area where the bronchus enters the lung (hilar
lymph nodes). These lymph nodes are on the same side as the
cancer (N1). The cancer has not spread to distant parts of the
body (M0).
OR
T3
N0

The tumor has one or more of the following features (T3):
•

It is larger than 5 cm but not larger than 7 cm across.
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M0

•

It has grown into the chest wall, the inner lining of the
chest wall (parietal pleura), the phrenic nerve, or
membranes of the sac surrounding the heart (parietal
pericardium).

•

There are 2 or more separate tumor nodules in the same
lobe of a lung.

The cancer has not spread to nearby lymph nodes (N0) or
distant parts of the body (M0).
The cancer is no larger than 3 cm across, has not grown into the
membranes that surround the lungs, and does not affect the
T1a/T1b/T1c
N2
M0

main branches of the bronchi (T1). The cancer has spread to
lymph nodes around the carina (the point where the windpipe
splits into the left and right bronchi) or in the space between the
lungs (mediastinum). These lymph nodes are on the same side
as the main lung tumor (N2). The cancer has not spread to
distant parts of the body (M0).
OR

IIIA

The tumor has one or more of the following features (T2):
T2a/T2b
N2

•

It is larger than 3 cm but not larger than 5 cm across.

M0

•

It has grown into a main bronchus, but is not within 2
cm of the carina (the point where the windpipe splits
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into the left and right main bronchi) and it is not larger
than 5 cm across.
•

It has grown into the visceral pleura (the membranes
surrounding the lungs) and is not larger than 5 cm.

•

It is partially clogging the airways (and is not larger than
5 cm).

The cancer has spread to lymph nodes around the carina (the
point where the windpipe splits into the left and right bronchi)
or in the space between the lungs (mediastinum). These lymph
nodes are on the same side as the main lung tumor (N2). The
cancer has not spread to distant parts of the body (M0).
OR
The tumor has one or more of the following features (T3):
•

It is larger than 5 cm but not larger than 7 cm across.

•

It has grown into the chest wall, the inner lining of the
chest wall (parietal pleura), the phrenic nerve, or

T3

membranes of the sac surrounding the heart (parietal

N1

pericardium).

M0
•

There are 2 or more separate tumor nodules in the same
lobe of a lung.

The cancer has also spread to lymph nodes within the lung
and/or around the area where the bronchus enters the lung (hilar
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lymph nodes). These lymph nodes are on the same side as the
cancer (N1). The cancer has not spread to distant parts of the
body (M0).
OR
The tumor has one or more of the following features (T4):
•

It is larger than 7 cm across.

•

It has grown into the space between the lungs
(mediastinum), the heart, the large blood vessels near the
heart (such as the aorta), the windpipe (trachea), the tube
connecting the throat to the stomach (esophagus), the

T4

thin muscle separating the chest from the abdomen

N0 or N1
M0

(diaphragm), the backbone, or the carina.
•

There are 2 or more separate tumor nodules in different
lobes of the same lung.

The cancer may or may not have spread to lymph nodes within
the lung and/or around the area where the bronchus enters the
lung (hilar lymph nodes). Any affected lymph nodes are on the
same side as the cancer (N0 or N1). The cancer has not spread
to distant parts of the body (M0).
T1a/T1b/T1c The cancer is no larger than 3 cm across, has not grown into the
N3

membranes that surround the lungs, and does not affect the

M0

main branches of the bronchi (T1). The cancer has spread to
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lymph nodes near the collarbone on either side of the body,
and/or has spread to hilar or mediastinal lymph nodes on the
other side of the body from the main tumor (N3). The cancer
has not spread to distant parts of the body (M0).
OR
The tumor has one or more of the following features (T2):
•

It is larger than 3 cm but not larger than 5 cm across.

•

It has grown into a main bronchus, but is not within 2
cm of the carina (the point where the windpipe splits
into the left and right main bronchi) and it is not larger

IIIB

than 5 cm across.
T2a/T2b

•

N3
M0

It has grown into the visceral pleura (the membranes
surrounding the lungs) and is not larger than 5 cm.

•

It is partially clogging the airways (and is not larger than
5 cm).

The cancer has spread to lymph nodes near the collarbone on
either side of the body, and/or has spread to hilar or mediastinal
lymph nodes on the other side of the body from the main tumor
(N3). The cancer has not spread to distant parts of the body
(M0).
OR
T3

The tumor has one or more of the following features (T3):
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N2
M0

•

It is larger than 5 cm but not larger than 7 cm across.

•

It has grown into the chest wall, the inner lining of the
chest wall (parietal pleura), the phrenic nerve, or
membranes of the sac surrounding the heart (parietal
pericardium).

•

There are 2 or more separate tumor nodules in the same
lobe of a lung.

The cancer has spread to lymph nodes around the carina (the
point where the windpipe splits into the left and right bronchi)
or in the space between the lungs (mediastinum). These lymph
nodes are on the same side as the main lung tumor (N2). The
cancer has not spread to distant parts of the body (M0).
OR
The tumor has one or more of the following features (T4):

T4
N2
M0

•

It is larger than 7 cm across.

•

It has grown into the space between the lungs
(mediastinum), the heart, the large blood vessels near the
heart (such as the aorta), the windpipe (trachea), the tube
connecting the throat to the stomach (esophagus), the
thin muscle separating the chest from the abdomen
(diaphragm), the backbone, or the carina (the point
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where the windpipe splits into the left and right main
bronchi).
•

There are 2 or more separate tumor nodules in different
lobes of the same lung.

The cancer has spread to lymph nodes around the carina (the
point where the windpipe splits into the left and right bronchi)
or in the space between the lungs (mediastinum). These lymph
nodes are on the same side as the main lung tumor (N2). The
cancer has not spread to distant parts of the body (M0).
The tumor has one or more of the following features (T3):
•

It is larger than 5 cm but not larger than 7 cm across.

•

It has grown into the chest wall, the inner lining of the
chest wall (parietal pleura), the phrenic nerve, or
membranes of the sac surrounding the heart (parietal

T3
N3

pericardium).
•

M0
IIIC

There are 2 or more separate tumor nodules in the same
lobe of a lung.

The cancer has spread to lymph nodes near the collarbone on
either side of the body, and/or has spread to hilar or mediastinal
lymph nodes on the other side of the body from the main tumor
(N3). The cancer has not spread to distant parts of the body
(M0).

70

OR
The tumor has one or more of the following features (T4):
•

It is larger than 7 cm across.

•

It has grown into the space between the lungs
(mediastinum), the heart, the large blood vessels near the
heart (such as the aorta), the windpipe (trachea), the tube
connecting the throat to the stomach (esophagus), the
thin muscle separating the chest from the abdomen

T4

(diaphragm), the backbone (spine), or the carina (the

N3

point where the windpipe splits into the left and right

M0

main bronchi).
•

There are 2 or more separate tumor nodules in different
lobes of the same lung.

The cancer has spread to lymph nodes near the collarbone on
either side of the body, and/or has spread to hilar or mediastinal
lymph nodes on the other side of the body from the main tumor
(N3). The cancer has not spread to distant parts of the body
(M0).
Any T
Any N
IVA

M1a

The cancer can be any size and may or may not have grown into
nearby structures (any T). It may or may not have reached
nearby lymph nodes (any N). In addition, any of the following
is true (M1a):
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•

The cancer has spread to the other lung.

•

Cancer cells are found in the fluid around the lung
(called a malignant pleural effusion).

•

Cancer cells are found in the fluid around the heart
(called a malignant pericardial effusion).
OR

The cancer can be any size and may or may not have grown into
Any T

nearby structures (any T). It may or may not have reached

Any N

nearby lymph nodes (any N). It has spread as a single tumor

M1b

outside of the chest, such as to a distant lymph node or an organ
such as the liver, bones, or brain (M1b).
The cancer can be any size and may or may not have grown into

IVB

Any T

nearby structures (any T). It may or may not have reached

Any N

nearby lymph nodes (any N). It has spread as more than one

M1c

tumor outside the chest, such as to distant lymph nodes and/or
to other organs such as the liver, bones, or brain (M1c).

Note: *The following additional categories are not listed in the table above:
•

T0: There is no evidence of a primary tumor.

•

NX: Nearby lymph nodes cannot be assessed due to lack of information.
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Appendix B – Regions Hospital permission to access data
From: Bellefy, Rebecca R
Sent: Wednesday, November 06, 2019 10:43 AM
To: 'erin-hamar@bethel.edu'; 'megan-biegler@bethel.edu'; 'stephanie-spinolo@bethel.edu'
Cc: Hurley, Peter J
Subject: Welcome to Your PA QI-Research Student Rotation
Welcome! We are excited to have you start your PA research project with Oncology
rotation at Regions Hospital. Your orientation will be on Wed. November 13th, 2019.
The following information will guide you through your first day and provide important
information for a successful rotation. Please note that you will also receive another email a
few weeks before your rotation with additional details of your schedule.
Parking
On your first day, please park in the West parking ramp located on Jackson St. Enter the
ramp on Jackson at 14th St. and park on Level F or G (top floor). Please bring your
parking ticket with you to have it validated. After your first day, you will be assigned to
the Robert Street Ramp, located on the corner of Robert St. and University Ave. Student
parking is $10.00 per calendar month. You must bring cash or a check to pay for a student
parking pass. Make sure to have your car information with you (license plate number,
make and model).
Your first day
Please come to the Internal Medicine Education office at 3:30 p.m. on November 13th.
Our office is located on the 7th floor of the Central Building, Room C7379. Follow the
signs for the Central Building when you enter the hospital from the West parking ramp.
We are the office immediately to your left as you step off the Central elevator. I’ll go over
the following:
 Help get your parking arranged.
 Help get your Regions Hospital badge.
 Take you on a tour to see the location of:
o Regions Hospital Auditorium (where you’ll go for IM Grand Rounds),
3rd Floor East – every Weds., from 12-1
o Student/ Resident Training Room (where you’ll go to attend Medical
Student Lectures), Room S2221 – over the noon hour most days (I’ll
show you where the schedule is located)
o Cafeteria and coffee shop
o Check your Epic access to make sure you can access the system.
o Review Amion.com (logon: regions) to show you how to page
someone.
 After we’re done, I’ll take you up to the Library for you to begin your QI –
Research Project.
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Important information for your rotation at Regions Hospital
 Dress code is business causal (no jeans). If you have a white coat, we ask that
students wear their white coat.
EPIC Training
An Epic Training Packet is attached for your reference.
Actions for You
• Flu Shot: You are required to report your influenza vaccination status. Bring your
completed form with you, so I can give you an orange clip for your badge to
show you have been vaccinated.
 We have an online tool that we use for capturing information about your rotation
at Regions Hospital, called New Innovations (NI). This tool helps to track students’
information and clinical hours at HealthPartners/ Regions Hospital over time.
 To log into NI, go to the website: www.new-innov.com. Then click on the
“Client Login” button in the upper right corner. From here you will see a log-in
screen where you will enter the information above to get logged in. You will be
directed to reset your password. Then, you will be directed to your home page
where you will see a link to your Onboarding Checklist.
 As you know, Dr. Hurley will be your lead preceptor and is the person who
should sign your Student Packet (explained and included in your Onboarding
Checklist). His email address is: Peter.J.Hurley@HealthPartners.Com
If you should have any questions, please feel free to contact me.
Looking forward to meeting you in person!
Attachment: Epic Training Packet
Regions Map
Flu Vaccine Form & Schedule
Best Regards,
Rebecca R. Bellefy
Program Associate
Office of Health Professional Education
Regions Hospital, 640 Jackson Street | MS: 11107E | St. Paul, MN, 55101
Office: 651-254-3486 | Fax: 651-254-3662
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Appendix C – Regions oncology department patient reported outcome measures (PROM)
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Appendix D – Excel spreadsheet for analysis between January 2019 and March 2020
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Appendix E – Research advisory agreement
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Appendix F – Regions Hospital IRB approval form

March 10, 2020
Regions Hospital Oncology
RE: Immediate Palliative Care Involvement in Metastatic Lung Cancer

This letter is to inform you that the HealthPartners Institute Research Subjects Protection
Program (RSPP) Office has reviewed your request for a determination of human subjects research
for the above referenced project.
The Office has determined that this project is a quality improvement initiative and does not meet
the definition of Human Subjects Research (45 CFR 46.102(d)). Therefore, no additional IRB
review or oversight is required at this time.
If the design of this project changes such that you or others at HealthPartners may be conducting
research with human subjects, then please contact the RSPP Office to review these changes prior
to implementation.

If you have any questions regarding this communication, please contact me at 952-967-5025 or
Amy.A.Fehrer@HealthPartners.Com. Thank you.

Sincerely,
Amy Fehrer, MPH
Senior Manager, Research Subjects Protection Program
HealthPartners Institute
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Appendix G – Bethel University IRB approval form

